In this narrative review, the authors concluded that while high-quality evidence for systemic therapies in pediatric alopecia areata is scarce, Janus kinase inhibitors have the most systematic support, with oral minoxidil and dupilumab also reported as potentially beneficial in certain cases.
December 2024 in “Clinical and Experimental Dermatology” In this study, researchers found that ritlecitinib, a JAK3/TEC inhibitor, significantly improves hair regrowth, quality of life, and psychological well-being in patients with severe alopecia areata who had inadequate or no response to baricitinib, a JAK1/2 inhibitor.
10 citations
,
October 2024 in “Dermatology Practical & Conceptual” This study found that dupilumab's effects on alopecia areata varied depending on patients' immune profiles, with Th2-skewed females seeing improvements and Th1-driven males experiencing worsening.
63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.
5 citations
,
July 2024 in “Pediatric Dermatology” This study reports that dupilumab significantly reduced alopecia areata severity in pediatric patients with atopic dermatitis, indicating potential as an effective treatment option, though further research on long-term safety and optimal use is needed.
6 citations
,
May 2024 in “Clinical and Experimental Dermatology” According to this systematic review, children with alopecia areata experience significant psychosocial impacts, including anxiety, depression, and lower self-esteem, which are exacerbated by increased disease severity and affect quality of life, academic performance, and social interactions.
4 citations
,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.
1 citations
,
December 2023 in “Journal of the European Academy of Dermatology and Venereology” 7 citations
,
November 2023 in “JAAD Case Reports” This study highlights the recent FDA approval of baricitinib as the first on-label treatment for severe alopecia areata, whereas previous treatments were off-label therapies like systemic steroids and immunosuppressants.
48 citations
,
July 2023 in “Pediatric Dermatology” This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.
91 citations
,
May 2023 in “Journal of Cutaneous Medicine and Surgery” Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.
April 2023 in “Journal of the American Academy of Dermatology” This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.
